News

Video

Putting Quality of Life into Perspective During CML Treatment

Author(s):

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning.

When discussing side effects from chronic myeloid leukemia (CML) treatment with the health care team, it is essential that patients state how their daily activities are affected, according to Claire Saxton.

In an interview at the 2024 American Society of Clinical Oncology Annual Meeting, Saxton, who is the executive vice president of Insights and Impact at Cancer Support Community, discussed the importance of quality of life while patients with CML undergo treatment.

“When you put things really in the perspective of how is this affecting your everyday life, your treatment team will be much better able to make sure that whatever treatment that you're on, it's the one that is giving you the best quality of life,” she said during an interview with CURE® at the conference.

WATCH MORE: 3 Questions to Ask Doctors After a CML Diagnosis

Transcript:

So, in the long term, the treatment journey really is how do we keep you having as few symptoms and side effects and as good a quality of life as possible. And so, being really clear with your treatment team [is important].

My fatigue means that I can't do some of my favorite things. … The fact that I have diarrhea means that I can't take the bus to work anymore.

When you put things really in the perspective of how is this affecting your everyday life, your treatment team will be much better able to make sure that whatever treatment that you're on, it's the one that is giving you the best quality of life.

Editor's Note: This program was made possible with support from Novartis Pharmaceuticals.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Related Content